Supporting RetiSpec’s Groundbreaking Alzheimer’s Diagnostic Innovation

On this page

Client Overview

RetiSpec is a health technology company developing an AI-based retinal imaging solution that enables early, non-invasive detection of Alzheimer’s disease, years before cognitive symptoms appear. Their platform offers an accessible and scalable alternative to traditional diagnostic methods like PET scans.

As their research and clinical validation efforts expanded, RetiSpec worked with Zero to One to help translate their cutting-edge work into a strong, fundable SR&ED claim.

Challenge

Although RetiSpec’s technology is highly sophisticated, communicating its scientific complexity within the rigid framework of the SR&ED program required thoughtful translation.

The challenge was not proving that RetiSpec was innovative, it was ensuring that their work was presented in a way that:

  • Clearly outlined the experimental development behind their AI platform
  • Avoided referencing proprietary or confidential technical configurations
  • Highlighted core uncertainties and advancements while preserving their IP strategy

Our team worked closely with RetiSpec’s technical leadership to unpack their development journey, clinical milestones, and integration challenges.

Finally, this was all structured this into a clear and defensible narrative aligned to the strict requirements of the SR&ED program.

Impact

Ultimately, we took a collaborative and investigative approach, building a deep understanding of both the technical arc of RetiSpec’s innovation and the operational complexity behind their clinical milestones. Our work served as a bridge between raw technical insight and the structured, auditable documentation that SR&ED demands.

By ensuring their new technology advancements were properly captured, we were able to significantly increase their SR&ED claim, nearly doubling the prior year’s total.

This was only possible because we clearly understood their product and how the technological uncertainty applied to software-hardware integration, without focusing on the physical components themselves. We also took a rigorous approach to framing experimental activities around AI reliability, reproducibility, and clinical performance.

Future Outlook

At Zero to One, we don’t just fill in forms. We dig into the engineering, understand the clinical realities, and structure claims that are both bold and defensible. And the result? RetiSpec will be able to reinvest a significantly larger amount of non-dilutive capital into further development of their proprietary system, fueling progress on protocol optimization, AI refinement, and clinical expansion. Their focus will

remain on validation at scale, regulatory readiness, and clinical integration.

And their next steps will require continued innovation.

Related posts

Your next funding opportunity is closing soon

Let’s connect before it's too late.